Open in Screener

KURA

Kura Oncology Inc

Aug 18 • 04:00PM ET

7.48

Dollar change +0.14
Percentage change 1.91	%

Healthcare • Biotechnology • USA • NASD

Peers: AGIO BLUE FATE ADAP EXEL IOVA KPTI FGEN

| Held by: VTI IWM XBI VXF IWN IBB SCHA AVUV VTWO JSMD

Index	RUT	P/E	-	EPS (ttm)	-2.26	Insider Own	4.64%	Shs Outstand	86.80M	Perf Week	35.02%
Market Cap	649.24M	Forward P/E	-	EPS next Y	-2.27	Insider Trans	0.60%	Shs Float	84.20M	Perf Month	17.61%
Enterprise Value	37.98M	PEG	-	EPS next Q	-0.72	Inst Own	93.64%	Short Float	9.39%	Perf Quarter	24.25%
Income	-197.17M	P/S	7.80	EPS this Y	-2.93%	Inst Trans	2.96%	Short Ratio	5.61	Perf Half Y	-9.66%
Sales	83.28M	P/B	2.13	EPS next Y	-9.42%	ROA	-32.93%	Short Interest	7.91M	Perf YTD	-14.12%
Book/sh	3.52	P/C	1.03	EPS next 5Y	3.47%	ROE	-51.11%	52W High	21.57 -65.32%	Perf Year	-60.71%
Cash/sh	7.27	P/FCF	5.28	EPS past 3/5Y	-0.89% -6.05%	ROIC	-61.59%	52W Low	5.41 38.26%	Perf 3Y	-53.25%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	98.95%	Volatility	8.25% 5.62%	Perf 5Y	-63.76%
Dividend TTM	-	EV/Sales	0.46	EPS Y/Y TTM	-1.26%	Oper. Margin	-263.82%	ATR (14)	0.41	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	6.16	Sales Y/Y TTM	-	Profit Margin	-236.76%	RSI (14)	68.78	Recom	1.21
Dividend Gr. 3/5Y	- -	Current Ratio	6.16	EPS Q/Q	-28.65%	SMA20	18.16%	Beta	0.18	Target Price	27.00
Payout	-	Debt/Eq	0.06	Sales Q/Q	-	SMA50	19.81%	Rel Volume	1.99	Prev Close	7.34
Employees	192	LT Debt/Eq	0.05	Earnings	Aug 07 AMC	SMA200	-7.65%	Avg Volume	1.41M	Price	7.48
IPO	Sep 16, 2015	Option/Short	Yes / Yes	EPS/Sales Surpr.	-104.97% -64.17%	Trades		Volume	2,805,903	Change	1.91%

Date	Action	Analyst	Rating Change	Price Target Change
Feb-06-25	Downgrade	BTIG Research	Buy → Neutral
Oct-24-24	Initiated	UBS	Buy	$27
Oct-14-24	Downgrade	Stifel	Buy → Hold	$26 → $19
Dec-22-23	Initiated	Mizuho	Buy	$26
Aug-11-23	Initiated	BofA Securities	Buy	$31
Jul-27-23	Initiated	Scotiabank	Sector Perform	$10.50
May-17-23	Initiated	BTIG Research	Buy	$31
Jan-31-23	Initiated	Stifel	Buy	$25
Jul-12-22	Initiated	Cantor Fitzgerald	Overweight	$30
Feb-15-22	Initiated	Jefferies	Buy	$35
May-05-21	Resumed	Credit Suisse	Outperform	$42
Apr-26-21	Resumed	Credit Suisse	Outperform	$42
Dec-07-20	Reiterated	H.C. Wainwright	Buy	$40 → $45
Dec-03-20	Initiated	Stifel	Buy	$45
Nov-05-20	Downgrade	Piper Sandler	Overweight → Neutral
Jul-07-20	Initiated	Credit Suisse	Outperform	$27
May-05-20	Initiated	Barclays	Overweight	$24
Jul-18-19	Initiated	Deutsche Bank	Buy	$28
Nov-09-18	Initiated	Piper Jaffray	Overweight
Aug-01-18	Initiated	H.C. Wainwright	Buy	$31

Show Previous Ratings

Aug-07-25 06:15PM	Kura Oncology (KURA) Reports Q2 Loss, Lags Revenue Estimates (Zacks) -7.05%
05:16PM	Kura Oncology: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	Kura Oncology Reports Second Quarter 2025 Financial Results (GlobeNewswire)
Aug-06-25 07:00AM	OMass Therapeutics Appoints Carol A. Schafer as Non-Executive Director and Chair of the Audit Committee (GlobeNewswire) -5.19%
Aug-04-25 07:30AM	Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
07:30AM	Loading…
Jul-31-25 07:30AM	Kura Oncology to Report Second Quarter 2025 Financial Results (GlobeNewswire)
Jul-03-25 07:30AM	Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-12-25 08:48AM	Is the Options Market Predicting a Spike in Kura Oncology Stock? (Zacks)
07:30AM	Kura Oncology and Kyowa Kirin Report Positive Updated Combination Data for Ziftomenib in Newly Diagnosed AML at 2025 European Hematology Association Congress (GlobeNewswire)
Jun-10-25 08:08PM	Lightning Round: 'Wait and see situation' with Papa John's, says Jim Cramer (CNBC TV)
Jun-06-25 11:52AM	KURA Stock Rises More Than 15% This Past Week: Here's Why (Zacks)
07:30AM	Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-02-25 06:00PM	Kura Oncology and Kyowa Kirin Report Positive Pivotal Ziftomenib Monotherapy Data at 2025 ASCO Annual Meeting (GlobeNewswire) +10.72%
Jun-01-25 07:00PM	Kura Oncology and Kyowa Kirin Announce FDA Acceptance and Priority Review of New Drug Application for Ziftomenib in Adults with Relapsed or Refractory NPM1-Mutant AML (GlobeNewswire)
May-22-25 05:30PM	Kura Oncology and Kyowa Kirin Announce Pivotal Monotherapy Data for Ziftomenib in Oral Presentation at the 2025 ASCO Annual Meeting (GlobeNewswire) -9.62%
07:30AM	Loading…
May-20-25 07:30AM	Kura Oncology to Participate in Three Upcoming Investor Conferences (GlobeNewswire)
May-14-25 10:00AM	Kura Oncology and Kyowa Kirin Announce Combination Data for Ziftomenib in Oral Presentation at the 2025 European Hematology Association (EHA) Congress (GlobeNewswire)
May-06-25 07:30AM	Kura Oncology to Participate in Bank of America Securities Healthcare Conference (GlobeNewswire) -13.84%
May-02-25 10:51AM	Q1 2025 Kura Oncology Inc Earnings Call (Thomson Reuters StreetEvents)
07:30AM	Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
03:17AM	Kura Oncology Inc (KURA) Q1 2025 Earnings Call Highlights: Strategic Advances Amid Rising Costs (GuruFocus.com)
May-01-25 08:48PM	Kura Oncology, Inc. (KURA) Q1 2025 Earnings Call Transcript (Seeking Alpha)
05:25PM	Kura Oncology (KURA) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
04:26PM	Kura Oncology: Q1 Earnings Snapshot (Associated Press Finance)
04:05PM	Kura Oncology Reports First Quarter 2025 Financial Results (GlobeNewswire)
Apr-29-25 05:27AM	Kura doses first subjects in trial of ziftomenib for advanced GIST (Clinical Trials Arena)
Apr-28-25 07:30AM	Kura Oncology Announces First Patients Dosed in Phase 1 Combination Trial of Ziftomenib for the Treatment of Advanced GIST (GlobeNewswire)
Apr-24-25 07:30AM	Kura Oncology to Report First Quarter 2025 Financial Results (GlobeNewswire)
Apr-08-25 07:30AM	Kura Oncology and Kyowa Kirin Announce Submission of New Drug Application for Ziftomenib to FDA (GlobeNewswire)
Apr-07-25 09:08AM	Syndax Pharmaceuticals: Down But Not Out (Seeking Alpha)
07:30AM	Loading…
Apr-04-25 07:30AM	Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Apr-01-25 07:30AM	Kura Oncology to Participate in Stifel Targeted Oncology Forum (GlobeNewswire)
Mar-26-25 07:30AM	Kura Oncology Announces Preclinical Data for KO-2806 Selected for Oral Presentation at the 2025 AACR Annual Meeting (GlobeNewswire)
Mar-07-25 07:30AM	Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Feb-27-25 11:19AM	Q4 2024 Kura Oncology Inc Earnings Call (Thomson Reuters StreetEvents)
02:24AM	Kura Oncology Inc (KURA) Q4 2024 Earnings Call Highlights: Strategic Advances and Financial Growth (GuruFocus.com)
Feb-26-25 05:35PM	Kura Oncology (KURA) Reports Q4 Loss, Lags Revenue Estimates (Zacks)
04:42PM	Kura Oncology: Q4 Earnings Snapshot (Associated Press Finance)
04:03PM	Kura Oncology Reports Fourth Quarter and Full Year 2024 Financial Results (GlobeNewswire)
Feb-25-25 07:30AM	Kura Oncology to Participate in Three Upcoming Investor Conferences (GlobeNewswire)
Feb-19-25 07:30AM	Kura Oncology to Report Fourth Quarter and Full Year 2024 Financial Results (GlobeNewswire)
Feb-07-25 07:30AM	Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Feb-05-25 04:01PM	Kura Oncology and Kyowa Kirin Announce Positive Ziftomenib Monotherapy Registrational Trial and Positive FDA Feedback for Upcoming Frontline Combination Trial Designs (GlobeNewswire)
Jan-06-25 04:30PM	Kura Oncology Announces Senior Executive Promotions (GlobeNewswire)
Dec-09-24 07:00AM	Kura Oncology and Kyowa Kirin Report Positive Combination Data for Ziftomenib at American Society of Hematology Annual Meeting (GlobeNewswire)
Dec-04-24 01:25PM	Why Is Kura Oncology, Inc. (KURA) Among the Best Small-Cap Biotech Stocks With Massive Potential According to Hedge Funds? (Insider Monkey)
Dec-02-24 07:30AM	Kura Oncology to Host Virtual Investor Event on December 9, 2024 (GlobeNewswire)
Nov-25-24 07:30AM	Kura Oncology to Participate in JMP Securities Hematology and Oncology Summit (GlobeNewswire)
Nov-23-24 10:42AM	Kura Oncology, Inc. (KURA): Among the Most Promising Cancer Stocks According to Hedge Funds (Insider Monkey)
Nov-22-24 05:30AM	Halozyme drops Evotec buyout bid; Patient dies in Neurogene trial (BioPharma Dive) +7.36%
Nov-21-24 04:15PM	Kura Crashes 37% After $1.53 Billion Deal Slams The Door On A Takeover (Investor's Business Daily) -36.77%
09:05AM	Kura Oncology Slams The Door On Its Takeover Narrative, And Shares Collapse 26% (Investor's Business Daily)
06:37AM	Kura Oncology partners Kyowa Kirin to advance AML treatment (Pharmaceutical Technology)
Nov-20-24 05:00PM	Kura Oncology and Kyowa Kirin Announce Global Strategic Collaboration to Develop and Commercialize Ziftomenib in Acute Leukemias (PR Newswire)
Nov-08-24 04:01PM	Kura Oncology Inc (KURA) Q3 2024 Earnings Call Highlights: Strategic Advances Amid Rising Expenses (GuruFocus.com)
Nov-07-24 05:15PM	Kura Oncology: Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	Kura Oncology Reports Third Quarter 2024 Financial Results (GlobeNewswire)
Nov-05-24 09:09AM	Kura Oncology to Present Updated Data from KOMET-007 Combination Trial of Ziftomenib at ASH Annual Meeting (GlobeNewswire)
Oct-31-24 07:30AM	Kura Oncology to Report Third Quarter 2024 Financial Results (GlobeNewswire)
Oct-29-24 08:00AM	Cartography Announces Appointment of Troy Wilson, Ph.D., J.D., to its Board of Directors (Business Wire)
Oct-24-24 07:30AM	Kura Oncology Reports Preclinical Data Supporting Opportunity for Ziftomenib in Treatment of Gastrointestinal Stromal Tumors (GIST) (GlobeNewswire)
Oct-23-24 07:30AM	Kura Oncology to Present New Data Supporting Combination of KO-2806 with KRAS G12C and Pan-RAS Inhibitors (GlobeNewswire)
Oct-09-24 05:54PM	Kura Oncology Inc (KURA) Q2 2024 Earnings Call Highlights: Strategic Advances Amid Rising Costs (GuruFocus.com)
Sep-30-24 06:30PM	Kura Oncology Announces Publication of Ziftomenib Phase 1 Results in The Lancet Oncology (GlobeNewswire)
Sep-17-24 07:30AM	Kura Oncology Appoints Michael Vasconcelles, M.D., to Board of Directors (GlobeNewswire)
Sep-10-24 07:30AM	Kura Oncology to Participate in Cantor Global Healthcare Conference (GlobeNewswire)
Sep-05-24 12:01AM	Kura Oncology, Inc. (KURA): This Small-Cap Healthcare Stock Is A Good Buy Right Now (Insider Monkey)
Sep-02-24 05:22PM	10 Best Small-Cap Healthcare Stocks To Buy Now (Insider Monkey)
Aug-08-24 04:44PM	Kura Oncology: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	Kura Oncology Reports Second Quarter 2024 Financial Results (GlobeNewswire)
07:30AM	Kura Oncology Announces FDA Clearance of IND Application for Menin Inhibitor Ziftomenib in Advanced Gastrointestinal Stromal Tumors (GIST) (GlobeNewswire)
Aug-01-24 07:30AM	Kura Oncology to Report Second Quarter 2024 Financial Results (GlobeNewswire)
Jul-05-24 07:30AM	Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-24-24 07:30AM	Kura Oncology Reports Preclinical Data Supporting Potential for Menin Inhibitor in Diabetes (GlobeNewswire)
Jun-17-24 09:00AM	Acute Myeloid Leukemia is on the Rise as Biotechs Race to Develop Groundbreaking Therapies (GlobeNewswire)
Jun-07-24 07:30AM	Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
May-29-24 07:30AM	Kura Oncology to Participate in Jefferies Global Healthcare Conference (GlobeNewswire)
May-14-24 11:44AM	Kura Oncology Enrolls 85 Patients in Ziftomenib Trial for Leukemia Drug (MT Newswires)
07:30AM	Kura Oncology Completes Enrollment in Registration-Directed Trial of Ziftomenib in NPM1-Mutant AML (GlobeNewswire)
May-08-24 08:30AM	2 Incredible Growth Stocks to Buy Hand Over Fist (Motley Fool)
07:30AM	Kura Oncology to Participate in Bank of America Securities Healthcare Conference (GlobeNewswire)
May-06-24 10:14AM	Kura Oncology, Inc. (NASDAQ:KURA) Q1 2024 Earnings Call Transcript (Insider Monkey)
May-03-24 07:30AM	Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
04:03AM	Kura Oncology Inc (KURA) (Q1 2024) Earnings Call Transcript Highlights: Key Financial and ... (GuruFocus.com)
May-02-24 08:58PM	KURA Stock Earnings: Kura Oncology Misses EPS for Q1 2024 (InvestorPlace)
04:48PM	Kura Oncology: Q1 Earnings Snapshot (Associated Press Finance)
04:05PM	Kura Oncology Reports First Quarter 2024 Financial Results (GlobeNewswire)
Apr-25-24 07:30AM	Kura Oncology to Report First Quarter 2024 Financial Results (GlobeNewswire)
Apr-22-24 07:30AM	Kura Oncology Receives Breakthrough Therapy Designation for Ziftomenib in NPM1-Mutant AML (GlobeNewswire)
Apr-10-24 07:30AM	Kura Oncology to Participate in Stifel Targeted Oncology Forum (GlobeNewswire)
Apr-05-24 07:30AM	Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Mar-06-24 07:30AM	Kura Oncology Reports First Patient Dosed in Trial of KO-2806 Plus Cabozantinib in Renal Cell Carcinoma (GlobeNewswire) +7.89%
Mar-01-24 05:00PM	Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Feb-28-24 09:56AM	Kura Oncology, Inc. (NASDAQ:KURA) Q4 2023 Earnings Call Transcript (Insider Monkey)
06:56AM	Q4 2023 Kura Oncology Inc Earnings Call (Thomson Reuters StreetEvents)
Feb-27-24 04:44PM	Kura Oncology Inc (KURA) Reports Q4 and Full Year 2023 Financial Results (GuruFocus.com)
04:10PM	Kura Oncology: Q4 Earnings Snapshot (Associated Press Finance)
04:01PM	Kura Oncology Reports Fourth Quarter and Full Year 2023 Financial Results (GlobeNewswire)
Feb-26-24 07:30AM	Kura Oncology Doses First Patient in KOMET-008 Trial of Ziftomenib in Combination with Standards of Care, Including FLT3 Inhibitor, in Acute Myeloid Leukemia (GlobeNewswire)
Feb-22-24 07:30AM	Kura Oncology to Participate in Three Upcoming Investor Conferences (GlobeNewswire)

Kura Oncology, Inc. operates as a clinical-stage biopharmaceutical company, which engages in the research and development of medicines for the treatment of cancer. Its pipeline includes Tipifarnib, which is a Farnesyl transferase inhibitor for HRAS Mutant Solid Tumors, Chronic Myelomonocytic Leukemia, KO-947, which is an ERK inhibitor for MAPK Pathway Tumors, and KO-539, which is a Menin MLL inhibitor for acute leukemias. The company was founded by Troy E. Wilson, Yi Liu, Pingda Ren and Antonio Gualberto on August 22, 2014 and is headquartered in San Diego, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
WILSON TROY EDWARD	President and CEO	Aug 12 '25	Buy	5.85	36,506	213,578	37,474	Aug 14 04:05 PM
WILSON TROY EDWARD	President and CEO	Aug 13 '25	Buy	6.64	13,494	89,623	50,968	Aug 14 04:05 PM
Bair Teresa Brophy	Chief Legal Officer	May 19 '25	Sale	5.96	1,559	9,292	107,948	May 19 06:30 PM
FORD KATHLEEN	Chief Operating Officer	May 19 '25	Sale	6.28	1,558	9,777	21,367	May 19 06:30 PM
FORD KATHLEEN	Officer	May 19 '25	Proposed Sale	5.96	1,558	9,286		May 19 04:06 PM
Hasnain Faheem	Director	Mar 21 '25	Option Exercise	6.32	22,682	143,350	46,665	Mar 24 04:33 PM
Hasnain Faheem	Director	Mar 21 '25	Sale	8.00	22,682	181,456	23,983	Mar 24 04:33 PM
FAHEEM HASNAIN	Director	Mar 21 '25	Proposed Sale	7.85	30,000	235,500		Mar 21 04:21 PM
DOYLE THOMAS JAMES	SVP, Finance & Accounting	Jan 28 '25	Sale	7.87	4,949	38,958	88,193	Jan 28 08:54 PM
Leoni Mollie	Chief Medical Officer	Jan 28 '25	Sale	7.87	4,963	39,068	88,253	Jan 28 08:39 PM
Bair Teresa Brophy	Chief Legal Officer	Jan 28 '25	Sale	7.87	7,281	57,315	107,948	Jan 28 08:38 PM
FORD KATHLEEN	Chief Operating Officer	Jan 28 '25	Sale	7.87	1,817	14,303	21,367	Jan 28 08:38 PM
Burrows Francis	Chief Scientific Officer	Jan 28 '25	Sale	7.87	2,166	17,051	20,705	Jan 28 08:38 PM
Powl Brian T.	Chief Commercial Officer	Jan 28 '25	Sale	7.87	1,583	12,461	59,667	Jan 28 08:38 PM
LEONI MOLLIE	Officer	Jan 28 '25	Proposed Sale	7.77	4,963	38,563		Jan 28 08:37 PM
BAIR TERESA BROPHY	Officer	Jan 28 '25	Proposed Sale	7.77	7,281	56,573		Jan 28 08:37 PM
FORD KATHLEEN	Officer	Jan 28 '25	Proposed Sale	7.77	1,817	14,118		Jan 28 08:37 PM
DOYLE THOMAS JAMES	Officer	Jan 28 '25	Proposed Sale	7.77	4,949	38,454		Jan 28 08:37 PM
BURROWS FRANCIS	Officer	Jan 28 '25	Proposed Sale	7.77	2,166	16,830		Jan 28 08:37 PM
POWL BRIAN T	Officer	Jan 28 '25	Proposed Sale	7.77	1,583	12,300		Jan 28 08:36 PM
FORD KATHLEEN	Chief Operating Officer	Nov 18 '24	Sale	16.03	526	8,434	23,184	Nov 19 04:05 PM
FORD KATHLEEN	Officer	Nov 18 '24	Proposed Sale	15.99	526	8,410		Nov 18 04:03 PM

Open in Screener

GOSS

Gossamer Bio Inc

Aug 18 • 04:00PM ET

1.99

Dollar change +0.03
Percentage change 1.53	%

Healthcare • Biotechnology • USA • NASD

Peers: BLUE CRSP SRPT FATE NTLA ADAP EDIT QURE BMRN VYGR

| Held by: VTI IWM VXF IWO VTWO SCHA IWC VTWG SCHB SBIO

Index	RUT	P/E	-	EPS (ttm)	-0.61	Insider Own	19.64%	Shs Outstand	227.32M	Perf Week	14.70%
Market Cap	452.49M	Forward P/E	-	EPS next Y	-0.47	Insider Trans	0.00%	Shs Float	182.73M	Perf Month	17.06%
Enterprise Value	442.40M	PEG	-	EPS next Q	-0.19	Inst Own	61.45%	Short Float	10.26%	Perf Quarter	91.35%
Income	-138.74M	P/S	11.24	EPS this Y	-167.09%	Inst Trans	8.81%	Short Ratio	7.29	Perf Half Y	51.91%
Sales	40.24M	P/B	-	EPS next Y	29.11%	ROA	-45.17%	Short Interest	18.75M	Perf YTD	119.99%
Book/sh	-0.20	P/C	2.13	EPS next 5Y	5.92%	ROE	-783.37%	52W High	2.23 -10.76%	Perf Year	140.63%
Cash/sh	0.94	P/FCF	-	EPS past 3/5Y	56.92% 40.29%	ROIC	-89.03%	52W Low	0.66 200.74%	Perf 3Y	-84.98%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	93.26%	Volatility	7.20% 8.96%	Perf 5Y	-85.09%
Dividend TTM	-	EV/Sales	10.99	EPS Y/Y TTM	-57.23%	Oper. Margin	-361.91%	ATR (14)	0.15	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	4.40	Sales Y/Y TTM	-58.02%	Profit Margin	-344.81%	RSI (14)	59.63	Recom	1.44
Dividend Gr. 3/5Y	- -	Current Ratio	4.40	EPS Q/Q	-181.59%	SMA20	3.04%	Beta	1.94	Target Price	7.75
Payout	-	Debt/Eq	-	Sales Q/Q	-88.01%	SMA50	25.04%	Rel Volume	0.57	Prev Close	1.96
Employees	145	LT Debt/Eq	-	Earnings	Aug 05 AMC	SMA200	72.25%	Avg Volume	2.57M	Price	1.99
IPO	Feb 08, 2019	Option/Short	Yes / Yes	EPS/Sales Surpr.	4.01% 112.41%	Trades		Volume	1,467,828	Change	1.53%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-14-25	Initiated	Scotiabank	Sector Outperform	$11
Jun-25-24	Initiated	Oppenheimer	Outperform	$9
Apr-05-24	Resumed	Wedbush	Outperform	$4
Jul-27-23	Downgrade	UBS	Buy → Neutral	$8 → $1.25
Mar-07-23	Downgrade	Raymond James	Outperform → Mkt Perform
Mar-01-23	Initiated	Guggenheim	Neutral
Dec-07-22	Downgrade	SMBC Nikko	Outperform → Neutral	$3
Dec-07-22	Downgrade	JP Morgan	Neutral → Underweight
Dec-07-22	Downgrade	Barclays	Overweight → Equal Weight	$18 → $2
Oct-20-22	Initiated	Goldman	Buy	$22
Sep-21-22	Initiated	JP Morgan	Neutral	$17
Sep-19-22	Initiated	Wedbush	Outperform	$24
Apr-18-22	Initiated	Raymond James	Outperform	$19
Apr-06-22	Initiated	UBS	Buy	$19
Jan-10-22	Upgrade	SMBC Nikko	Neutral → Outperform	$24
Nov-09-21	Resumed	Cantor Fitzgerald	Overweight	$20
Sep-21-21	Resumed	Piper Sandler	Overweight	$26
Jun-29-20	Initiated	H.C. Wainwright	Buy	$31
Apr-22-20	Initiated	Piper Sandler	Overweight	$30
Feb-27-20	Initiated	Barclays	Overweight	$21

Show Previous Ratings

Today 12:06AM	H.C. Wainwright and Leerink Partners Reiterate 'Buy' Ratings on Gossamer Bio, Inc. (GOSS) (Insider Monkey)
Aug-07-25 05:30PM	Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -12.12%
Aug-05-25 05:55PM	Gossamer Bio (GOSS) Reports Q2 Loss, Beats Revenue Estimates (Zacks) -8.33%
04:53PM	Gossamer Bio: Q2 Earnings Snapshot (Associated Press Finance)
04:01PM	Gossamer Bio Announces Second Quarter 2025 Financial Results and Provides Business Update (Business Wire)
08:40AM	Loading…
08:40AM	Harmony Biosciences Holdings, Inc. (HRMY) Misses Q2 Earnings and Revenue Estimates (Zacks)
Jul-30-25 07:05AM	GSK (GSK) Q2 Earnings and Revenues Beat Estimates (Zacks) +6.12%
Jun-24-25 12:46PM	Gossamer Bio Completes Enrollment for Phase 3 PROSERA Study of PAH Drug Seralutinib (Insider Monkey)
Jun-16-25 07:31AM	Gossamer Bio Announces Completion of Enrollment in Registrational Phase 3 PROSERA Study for the Treatment of PAH (Business Wire)
Jun-06-25 05:30PM	Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +5.56%
May-21-25 07:00AM	Presenting on Emerging Growth Conference 82 Day 2 on May 22; Register to live stream (GlobeNewswire)
May-16-25 09:11AM	Q1 2025 Gossamer Bio Inc Earnings Call (Thomson Reuters StreetEvents)
03:15AM	Gossamer Bio Inc (GOSS) Q1 2025 Earnings Call Highlights: Strategic Progress Amid Financial ... (GuruFocus.com)
May-15-25 05:15PM	Gossamer Bio (GOSS) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:09PM	Gossamer Bio: Q1 Earnings Snapshot (Associated Press Finance)
04:01PM	Loading…
04:01PM	Gossamer Bio Announces First Quarter 2025 Financial Results and Provides Business Update, Including Closure of New Patient Screening in Phase 3 PROSERA Study (Business Wire)
May-14-25 09:45AM	What To Expect From Gossamer Bio Inc (GOSS) Q1 2025 Earnings (GuruFocus.com) -7.34%
May-12-25 04:01PM	Gossamer Bio to Announce First Quarter 2025 Financial Results and Host Conference Call and Webcast on May 15, 2025 (Business Wire)
May-07-25 05:30PM	Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
04:01PM	Gossamer Bio to Present Preclinical Data at the American Thoracic Society (ATS) 2025 International Conference (Business Wire)
May-02-25 01:21PM	Gossamer Bio: Initiating Hold As Late-Stage Data Nears Inflection (Seeking Alpha) +11.32%
Apr-16-25 09:57AM	Is Gossamer Bio Inc. (NASDAQ:GOSS) the Best Penny Stock to Invest in Under $1? (Insider Monkey)
Apr-09-25 09:44AM	Gossamer Bio, Inc. (GOSS): Among Stocks Under $10 that Will Triple (Insider Monkey) +11.76%
Apr-08-25 05:30PM	Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Mar-27-25 09:45AM	Is Gossamer Bio Inc. (GOSS) the Popular Penny Stock on Robinhood to Watch? (InsiderMonkey)
Mar-26-25 01:38PM	Is Gossamer Bio, Inc. (GOSS) The Hot Biotech Stock Under $5? (InsiderMonkey) -7.81%
Mar-23-25 08:41AM	Gossamer Bio (GOSS): Among the Penny Stocks With Huge Upside Potential According to Analysts (InsiderMonkey)
Mar-13-25 05:10PM	Gossamer Bio (GOSS) Reports Q4 Loss, Tops Revenue Estimates (Zacks) +11.54%
04:06PM	Gossamer Bio: Q4 Earnings Snapshot (Associated Press Finance)
04:01PM	Gossamer Bio Announces Fourth Quarter and Full-Year 2024 Financial Results and Provides Business Update (Business Wire)
05:30PM	Loading…
Mar-07-25 05:30PM	Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Feb-19-25 06:00AM	Presenting on the Emerging Growth Conference 79 Day 2 on February 19 Register Now (GlobeNewswire)
Feb-07-25 05:30PM	Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +10.38%
Feb-03-25 07:01AM	Gossamer Bio Presented Clinical and Preclinical Data at the Pulmonary Vascular Research Institute 2025 Annual Congress (Business Wire)
Jan-28-25 07:01AM	Gossamer Bio to Present Clinical and Preclinical Data at the Pulmonary Vascular Research Institute 2025 Annual Congress (Business Wire)
Jan-07-25 05:30PM	Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -5.41%
09:19AM	Why Gossamer Bio, Inc. (GOSS) Is Among the Best Penny Stocks to Invest In According to Media? (Insider Monkey)
Dec-26-24 12:00PM	Gossamer Bio (GOSS) Upgraded to Buy: Here's What You Should Know (Zacks)
Nov-21-24 12:00PM	All You Need to Know About Gossamer Bio (GOSS) Rating Upgrade to Buy (Zacks)
Nov-15-24 09:35AM	After Plunging -20% in 4 Weeks, Here's Why the Trend Might Reverse for Gossamer Bio (GOSS) (Zacks)
Nov-14-24 09:35AM	After Plunging -15.92% in 4 Weeks, Here's Why the Trend Might Reverse for Gossamer Bio (GOSS) (Zacks) -5.59%
Nov-11-24 04:01PM	Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Nov-07-24 06:00PM	Gossamer Bio (GOSS) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
04:59PM	Gossamer Bio: Q3 Earnings Snapshot (Associated Press Finance)
04:03PM	Gossamer Bio Announces Third Quarter 2024 Financial Results and Provides Business Update (Business Wire)
Oct-31-24 07:00AM	NRx Pharmaceuticals added to Emerging Growth Conference 76 on October 31 and Update to Schedule (GlobeNewswire)
Oct-30-24 07:00AM	Presenting on the Emerging Growth Conference 76 Day 2 on October 31 Register Now (GlobeNewswire)
Oct-29-24 07:00AM	Presenting on the Emerging Growth Conference 76 Day 1 on October 30 Register Now (GlobeNewswire)
Oct-07-24 05:01PM	Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Sep-25-24 07:00AM	Presenting on the Emerging Growth Conference 75 Day 2 on September 26 (GlobeNewswire)
Sep-24-24 07:00AM	Presenting on the Emerging Growth Conference 75 Day 1 on September 25 Register Now (GlobeNewswire)
Aug-26-24 04:01PM	Gossamer Bio Announces Data Presentations at the European Respiratory Society Congress 2024 (Business Wire)
Aug-21-24 07:00AM	Presenting on the Emerging Growth Conference 74 Day 2 on August 22 Register Now (GlobeNewswire)
Aug-20-24 07:00AM	Presenting on the Emerging Growth Conference 74 Day 1 on August 21 Register Now (GlobeNewswire)
Aug-12-24 10:53PM	GOSS Stock Earnings: Gossamer Bio Misses EPS, Misses Revenue for Q2 2024 (InvestorPlace)
05:10PM	Gossamer Bio (GOSS) Q2 Earnings and Revenues Lag Estimates (Zacks)
04:15PM	Gossamer Bio: Q2 Earnings Snapshot (Associated Press Finance)
04:01PM	Gossamer Bio Announces Second Quarter 2024 Financial Results and Provides Business Update (Business Wire)
Jul-25-24 02:35AM	Why Is Gossamer Bio, Inc. (GOSS) the Best One-Dollar Stock to Buy Now? (Insider Monkey)
Jun-13-24 03:35PM	The Penny Stock Pundits: 3 Companies Poised to Become the Talk of Wall Street (InvestorPlace)
Jun-07-24 04:30PM	Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -8.60% -6.09%
May-14-24 04:01PM	Gossamer Bio to Provide Updated Seralutinib TORREY Open-Label Extension Data at the American Thoracic Society 2024 International Conference (Business Wire)
May-10-24 04:30PM	Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
May-07-24 10:56PM	GOSS Stock Earnings: Gossamer Bio Misses EPS for Q1 2024 (InvestorPlace) -6.30%
05:15PM	Gossamer Bio: Q1 Earnings Snapshot (Associated Press Finance)
04:01PM	Gossamer Bio Announces First Quarter 2024 Financial Results and Provides Business Update (Business Wire)
05:11AM	Gossamer Bio and Chiesi partner for pulmonary hypertension treatment (Pharmaceutical Technology)
04:31AM	Gossamer Bio and Chiesi link for pulmonary hypertension treatment (Pharmaceutical Technology)
May-06-24 03:17PM	Gossamer Bio Collaborates With Italian Drugmaker Chiesi To Advance Lung Health Solutions Worldwide (Benzinga) +5.50%
08:17AM	UPDATE 1-Gossamer Bio and Chiesi Group to collaborate in therapy for lung condition (Reuters)
08:11AM	Gossamer sells rights to drug it hopes can rival a new Merck therapy (BioPharma Dive)
07:41AM	Gossamer Bio and Chiesi Group to collaborate for blood pressure treatment (Reuters)
07:30AM	Gossamer Bio and Chiesi Group Announce Transformative Global Collaboration to Develop and Commercialize Seralutinib in PAH, PH-ILD & Other Indications (Business Wire)
May-03-24 08:02AM	Gossamer Bio Announces Publication of TORREY Phase 2 Results in the Lancet Respiratory Medicine (Business Wire)
Mar-13-24 07:07AM	13 Best Biotech Stocks To Buy Under $20 (Insider Monkey)
Mar-12-24 07:31AM	Gossamer Bio Announces Appointment of Steven D. Nathan, M.D., and Skye Drynan to its Board of Directors (Business Wire)
Mar-07-24 09:55AM	Should You Buy Gossamer Bio (GOSS) After Golden Cross? (Zacks) -7.95%
Mar-05-24 10:52PM	GOSS Stock Earnings: Gossamer Bio Meets EPS for Q4 2023 (InvestorPlace)
07:55AM	Gossamer Bio Posts Narrower Loss In Q4 - Quick Facts (RTT News)
07:40AM	Gossamer Bio: Q4 Earnings Snapshot (Associated Press Finance)
07:31AM	Gossamer Bio Announces Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update (Business Wire)
Feb-27-24 03:30AM	12 Best Medical Stocks to Buy Under $10 (Insider Monkey)
Jan-31-24 02:23PM	7 Micro-Cap Stocks That Could Majorly Surprise Investors (InvestorPlace)
Jan-22-24 10:53AM	5 Small-Cap Stocks with High Potential (Insider Monkey)
Jan-08-24 04:01PM	Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +8.24% +7.16%
Dec-13-23 04:01PM	Gossamer Bio to Host Webcast to Discuss Latest Seralutinib Open-Label Extension Data on December 18, 2023 (Business Wire)
Dec-05-23 04:01PM	Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +6.31%
07:01AM	Gossamer Bio Appoints Bob Smith as Chief Commercial Officer (Business Wire)
Nov-29-23 07:01AM	Gossamer Bio Announces Appointment of John Quisel, J.D., Ph.D., to its Board of Directors (Business Wire)
Nov-09-23 08:11AM	Gossamer Bio Inc (GOSS) Reports Q3 2023 Financial Results and Business Progress (GuruFocus.com) -7.56%
07:41AM	Gossamer Bio: Q3 Earnings Snapshot (Associated Press Finance)
07:31AM	Gossamer Bio Announces Third Quarter 2023 Financial Results and Provides Business Update (Business Wire)
Oct-23-23 10:08AM	12 Best Penny Stocks to Buy Under $1 (Insider Monkey) -6.46%
Oct-03-23 04:08PM	Gossamer Bio Announces Addition of Rainer Zimmermann, MD, as VP of Medical Affairs (Business Wire) -5.57%
Sep-07-23 07:44AM	Gossamer Bio to Present Results of TORREY FRI Sub-Study at the European Respiratory Society International Congress 2023 (Business Wire)
Aug-28-23 08:20AM	TENX: Second Quarter Results (Zacks)
Aug-08-23 04:41PM	Gossamer Bio: Q2 Earnings Snapshot (Associated Press Finance) -5.43%
04:01PM	Gossamer Bio Announces Second Quarter 2023 Financial Results and Provides Business Update (Business Wire)
Jul-24-23 04:16PM	Gossamer Bio to Hold Conference Call with PAH Experts to Discuss PROSERA Phase 3 Design and Interim TORREY OLE Results (Business Wire) -6.72%
Jul-20-23 07:56AM	Gossamer Bio Announces $212 Million Private Placement Financing (Business Wire) -31.87%

Gossamer Bio, Inc. engages in discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. Its primary product candidate, GB001, is intended for the treatment of moderate-to-severe eosinophilic asthma and other allergic conditions. The company was founded by Faheem Hasnain and Sheila Gujrathi on October 26, 2015 and is headquartered in San Diego, CA.

KURA

Kura Oncology Inc

GOSS

Gossamer Bio Inc

Upgrade your FINVIZ experience